Wenthe, Jessica http://orcid.org/0000-0003-4385-7568
Naseri, Sedigheh
Labani-Motlagh, Alireza
Enblad, Gunilla
Wikström, Kristina I.
Eriksson, Emma
Loskog, Angelica
Lövgren, Tanja
Funding for this research was provided by:
Barncancerfonden
Cancerfonden
Vetenskapsrådet
Uppsala University
Article History
Received: 8 October 2020
Accepted: 15 February 2021
First Online: 5 March 2021
Compliance with ethical standards
:
: AL is the CEO and board member of Lokon Pharma and an alternate board member and scientific advisor of NEXTTOBE, the owner of Lokon Pharma. EE is a part time employee of Lokon Pharma.
: CAR T cells used in this study were obtained from CAR T-cell batches produced for the clinical trial EudraCT 2013-001393-19/NCT02132624, which was approved by the Medical Product Agency in Sweden and by the regional ethical review board and were herein analyzed as part of their functionality testing. All patients signed informed consent. Animal experiments were approved by the local animal ethical review board in Uppsala, Sweden (DNr 5.8.18-13471/2017).
: Not applicable.